

Responding to the return of influenza in the United States: applying CDC surveillance, analysis, and modeling to inform understanding of seasonal influenza

Rebecca K. Borchering, Matthew Biggerstaff, Lynnette Brammer, Alicia Budd, Shikha Garg, Alicia M. Fry, A. Danielle Iuliano, Carrie Reed

Submitted to: JMIR Public Health and Surveillance
on: November 06, 2023

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript.....	4
Supplementary Files.....	19

Preprint
JMIR Publications

Responding to the return of influenza in the United States: applying CDC surveillance, analysis, and modeling to inform understanding of seasonal influenza

Rebecca K. Borchering¹; Matthew Biggerstaff¹; Lynnette Brammer¹; Alicia Budd¹; Shikha Garg¹; Alicia M. Fry²; A. Danielle Iuliano¹; Carrie Reed¹

¹National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Atlanta US

²Fulton County Board of Health Atlanta US

Corresponding Author:

Rebecca K. Borchering
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE MS H24-7

-
Atlanta
US

Abstract

We reviewed the tools that have been developed to characterize and communicate seasonal influenza activity in the United States. Here we focus on systematic surveillance and applied analytics including seasonal burden and disease severity estimation, short-term forecasting, and longer-term modeling efforts. For each set of activities, we describe challenges and opportunities that have arisen because of the COVID-19 pandemic. In conclusion, we highlight how collaboration and communication have been and will continue to be key components of reliable and actionable influenza monitoring, forecasting, and modeling activities.

(JMIR Preprints 06/11/2023:54340)

DOI: <https://doi.org/10.2196/preprints.54340>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in [http](#)

Original Manuscript

Submission type: Viewpoint

Title: Responding to the return of influenza in the United States: applying CDC surveillance, analysis, and modeling to inform understanding of seasonal influenza

Authors: Rebecca K. Borchering¹, Matthew Biggerstaff¹, Lynnette Brammer¹, Alicia Budd¹, Shikha Garg¹, Alicia M. Fry², A. Danielle Iuliano¹, Carrie Reed¹

¹ Epidemiology and Prevention Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

² Fulton County Board of Health, Atlanta, Georgia, USA.

Corresponding author: Rebecca K. Borchering

Centers for Disease Control and Prevention
1600 Clifton Rd NE MS H24-7; Atlanta, GA 30329-4027
Phone: +1 (404) 639-5214
Email: xhq2@cdc.gov

Keywords: seasonal influenza, surveillance, disease burden, modeling

Abstract: We reviewed the tools that have been developed to characterize and communicate seasonal influenza activity in the United States. Here we focus on systematic surveillance and applied analytics including seasonal burden and disease severity estimation, short-term forecasting, and longer-term modeling efforts. For each set of activities, we describe challenges and opportunities that have arisen because of the COVID-19 pandemic. In conclusion, we highlight how collaboration and communication have been and will continue to be key components of reliable and actionable influenza monitoring, forecasting, and modeling activities.

Context

The COVID-19 pandemic disrupted the typical timing, intensity, and duration of influenza virus activity in the United States and many parts of the world [1,2]. These disruptions are likely due in part to the adoption of non-pharmaceutical interventions (NPIs), such as mask wearing and physical distancing, that were deployed to prevent SARS-CoV-2 transmission and which likely also reduced

transmission of influenza viruses and other respiratory viruses [1]. Reductions in the use of NPIs in the United States during the 2022–2023 influenza season compared to what was observed during the 2020–2021 and 2021–2022 seasons, may have contributed to a return of influenza virus activity more comparable to levels observed during some pre-pandemic seasons, which had annual estimates of 9 million – 41 million illnesses, 140,000 – 710,000 hospitalizations and 12,000 – 52,000 deaths between 2010 and 2020 [3]. The interim estimated burden of influenza for the 2022-2023 influenza season indicated that between 27 - 54 million illnesses, 300,000 - 650,000 hospitalizations, and 19,000 to 58,000 deaths occurred that season [4]. The 2022 and the ongoing 2023 influenza seasons observed in the Southern Hemisphere winter (approximately May to September) were characterized by the circulation of multiple seasonal influenza viruses (i.e., influenza A/H3, A/H1, and B Victoria) [5]; atypical timing patterns, including early and late seasons; and/or increased intensity compared to recent seasons during the COVID-19 pandemic. However, changes in care seeking behaviors, testing practices, and general reporting practices due to the pandemic complicate the interpretation of influenza surveillance data.

The experience of the Southern Hemisphere in 2022 and 2023 [5] and atypically early and rapid start to the 2022-2023 influenza season in the United States [6,7,8] serve as reminders that seasonal influenza remains a major public health threat. Influenza burden during the 2022-23 season was elevated compared to activity observed in the United States during the first two years of the COVID-19 pandemic [4,9], and early and high rates of influenza-associated hospitalizations were observed, particularly in children [7,8,10]. Over the past decade, CDC's Influenza Division has worked internally and with external collaborators to develop, validate, and improve forecasting, mathematical modeling, and analytical tools that help translate U.S. influenza surveillance data into action by forecasting short-term influenza activity and characterizing the burden and severity within and across influenza seasons. With the decreased influenza activity observed in the 2020-2021 season, atypical activity and timing in the U.S. 2021-2022 and 2022-2023 seasons, and the Southern

Hemisphere's 2022 and 2023 seasons, continued circulation of SARS-CoV-2, and the return of other respiratory pathogens (e.g., Respiratory Syncytial Virus, RSV) [1,11], we summarize these activities to highlight how these tools can help inform influenza prevention and control efforts during future seasons in the post-pandemic respiratory virus landscape.

Data from surveillance systems provide the foundation for influenza situational awareness and risk communication.

Multiple surveillance systems provide complementary information to create a comprehensive picture of influenza activity in the United States [6,12]. These information streams are fundamental for situational awareness, risk communication, and subsequent modeling and analysis. Types of surveillance data collated and distributed by CDC include influenza hospitalizations (hospitalization rates by age, sex, and race/ethnicity, and clinical characteristics and outcomes) [9,13]; influenza-related mortality (the National Center for Health Statistics Mortality Surveillance Data and pediatric influenza-associated mortality), virologic (e.g., percent positivity, influenza virus type/subtype and genomic characterization of influenza viruses, which can be used to assess the match of circulating strains to vaccine components); and syndromic outpatient illness [12]. Maintaining these data sources requires coordination within CDC as well as with international organizations, vital statistics offices, state and local public health partners in both clinical and laboratory settings, hospitals, and healthcare providers.

Weekly FluView [6] reports provide systematic data updates and interpretation from the many influenza surveillance systems. These reports, related data updates, and visualizations provide a valuable resource for CDC, external partners, and the public to understand and interpret influenza activity. Regular and rapid dissemination of surveillance data that is easily accessible and interpretable plays an important role in risk communication and promotion of prevention and mitigation measures, such as vaccination, testing, antiviral use, and non-pharmaceutical

interventions.

Given the cocirculation of multiple respiratory viruses with potential to cause severe illness, interpreting influenza virus data alongside of complementary surveillance data for other respiratory viruses provides additional context to the added burden of influenza on the population and the healthcare system. Symptom based surveillance for influenza has traditionally been complicated, due in part to overlapping symptomology. Accordingly, data from the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINET), where outpatient visits are monitored for influenza-like illness defined as fever plus cough or sore throat, can include reports due to infection with co-circulating respiratory pathogens that may be clinically indistinguishable from influenza, including COVID-19 and RSV. In addition, changes in healthcare seeking behavior due to the COVID-19 pandemic, both in terms of provider choice and timing relative to illness onset and severity, will be important to consider when assessing surveillance data collected from healthcare settings. Additionally, the expansion of virtual/telehealth options will complicate surveillance, particularly for laboratory-based surveillance. The Influenza Division will continue to leverage the strengths of different surveillance systems to provide a comprehensive understanding of seasonal influenza virus activity. In addition, in order to better understand the burden of influenza in relation to other respiratory viruses like RSV and COVID-19 the Influenza Division has co-supported the development of multi-pathogen respiratory virus surveillance networks, and developed publicly facing summaries that compares acute respiratory illness emergency department visits for laboratory confirmed influenza, RSV, and COVID-19 [14] and weekly in-season rates of laboratory confirmed influenza, COVID-19 and RSV-associated hospitalizations by age, sex, and race/ethnicity [15]. Influenza surveillance and communication efforts will continue to adapt in the uncertain and changing landscape of continued respiratory virus cocirculation.

Estimating influenza disease incidence using analytic methods that account for the under-detection of influenza provides a more complete picture of the burden and severity of the influenza season.

Not all persons seek medical care for respiratory illnesses, and not all of those who do will be tested to confirm infection with a specific pathogen. Even when an individual seeks medical care and is tested, this may not occur during the time window of their illness when a collected sample has the potential to test positive (i.e., the pathogen or antibodies may no longer be detectable). A variety of viral and bacterial respiratory illnesses are clinically indistinguishable from one another, complicating diagnosis based on symptoms or clinical findings alone. Laboratory testing for specific pathogens can be more or less common in certain care settings, for different age groups, and at differing levels of disease severity. To account for the incomplete detection of influenza virus infection from clinical testing in healthcare settings, models used to estimate the disease burden incorporate information on healthcare utilization and laboratory testing for respiratory viruses [16]. Each year, CDC uses mathematical and statistical models to estimate the broader disease burden from influenza in the U.S. population; since 2018 this has been estimated weekly during the influenza season [17]. In the 2022-2023 season, the first preliminary in-season weekly influenza burden estimates were released in October [4], earlier than any other season due to the atypically high levels of influenza activity observed at that time of year.

The ongoing effects of the COVID-19 pandemic on healthcare utilization and testing for respiratory viruses [18], including influenza, are unclear and will likely continue to evolve over time. Major changes to healthcare seeking behaviors, including where patients are seeking care and the use of clinical vs. at-home diagnostic testing could influence trends observed in long-standing surveillance systems, impact ongoing efforts to forecast influenza activity, and introduce new biases into epidemiologic and clinical studies that rely on the results of clinical testing. CDC will continue to make estimates using the best available data, adapt to challenges presented by atypical seasonality,

and assess developments in care-seeking behaviors and influenza testing [19]. Communicating in season and end of season burden estimates through the CDC website and FluView reports will help promote public awareness and add to our understanding of influenza burden alongside of COVID-19 burden. These ongoing activities will ensure that influenza burden estimation continues to be improved utilizing the best available statistical methods and data sources.

Collaborative forecasting efforts hosted by CDC utilize surveillance data to look ahead and provide quantitative forecasts for short-term trends in influenza activity.

Although these traditional surveillance systems and disease burden estimates are comprehensive, they measure influenza activity after it has occurred, which limits their utility to anticipate future trends and inform risk assessment, resource allocation, and healthcare preparedness. To address these limitations, CDC has been collaborating with and supporting public health officials and researchers from academia, industry, and the government in open forecasting challenges since the 2013–2014 season [20]. This process has ensured that forecasting targets are relevant to public health; forecast data are openly available and communicated; and the evaluation of forecast performance across different targets, seasons, geographic locations, and methods is transparent [21–23]. This foundation helped lead to the rapid establishment of the COVID-19 Forecast Hub during early 2020 [24–26].

Building on 10 years of experience and working in collaboration with academic and industry partners, including two Centers of Excellence in Influenza Forecasting (the University of Massachusetts and Carnegie Mellon University), CDC has regularly communicated short-term forecasts at the national, state, and territory level for the 2023–2024 influenza season for the weekly number of patients hospitalized with laboratory-confirmed influenza based on data from the National Health Care Safety Network (NHSN) hospital admission system (previously known as HHS-Protect) [13,27]. This hospitalization-based forecast target was adopted during the 2021–2022 season when reporting of laboratory confirmed influenza hospital admissions became mandatory in February 2022

at the state- and hospital facility- level and is different than the forecast target used prior to the COVID-19 pandemic, which was based on outpatient visits for influenza-like illness (ILI) [20]. This shift was made because of changes in outpatient care seeking associated with the pandemic and the continued co-circulation of SARS-CoV-2 and RSV, which complicated the interpretation of ILI data, and the new availability of laboratory confirmed influenza hospital admission data through NHSN for all 50 states. This centralized source of virus specific hospitalization data may provide actionable and reliable information moving forward [28,29]. Experience from using the NHSN hospital admission indicator for influenza forecasting during the 2021–2022 and 2022-2023 influenza seasons [30], as well as during other forecasting and modeling efforts during the COVID-19 pandemic indicate that the NHSN hospital admission data [13], which became available during the COVID-19 pandemic, are a robust source of timely information about the impact of influenza in U.S. hospitals. Reported data include daily state-level counts of total hospitalized patients, previous day's admissions, and total hospitalized ICU patients each with laboratory-confirmed influenza virus infection [13].

Insights from past forecasting efforts, including for the COVID-19 pandemic and past influenza seasons, can provide users of forecasts valuable takeaways for interpreting influenza forecasts with appropriate levels of caution. First, forecasts are less reliable during periods of rapid change (e.g., during periods of sharp increases in incidence or when activity is peaking). During these periods, forecasts are often unable to reliably predict changing trends, and interim evaluation of early season forecasts received during the periods of the 2022–2023 season when influenza activity was increasing rapidly or peaking indicated that more reported hospitalizations than expected fell outside of the forecast prediction intervals, indicating a lack of forecast reliability. Improvements in forecasting methodology are needed to ensure that periods of rapid change can be forecasted reliably. Due to the unreliability of forecasts observed in these periods, the Influenza Division did not start public communication of these forecasts until observed performance became more reliable (January

2023). To begin addressing this limitation, the FluSight challenge [27] piloted a set of new forecast targets for probabilities of observing categorical changes in hospital admission trends, such as increases and decreases above certain thresholds, at state, territory, and national levels and will continue the use of these targets in the 2023-2024 season. Second, ensemble models typically outperform individual model forecasts, making them a more robust choice for forecasts with dependably accurate performance [22-24, 26]. Finally, forecast performance degrades as they predict farther into the future, as evidenced by higher performance of one-week ahead forecasts than two-, three-, and four-week ahead forecasts [22], and CDC may also pause communication of these longer horizon forecasts in periods of rapid change. In addition to the challenges associated with rapid increases, atypical seasonality and new data sources for forecasting present additional challenges for forecasting influenza during and following the COVID-19 pandemic since many forecasting models rely on historical data to inform predictions of seasonal trends. Ongoing discussions with academic and industry partners that complement collaborations with the Council for State and Territorial Epidemiologists (CSTE), including the pilot activities mentioned above, will help ensure that forecasting and modeling results are shared, discussed, and interpreted in a timely manner.

Additional modeling approaches are needed to increase our understanding of the potential severity and timing of the upcoming influenza seasons.

Inherent uncertainties in epidemiological conditions and effects of interventions over longer time horizons require different modeling frameworks than forecasting alone. Therefore, CDC started collaborating with the Scenario Modeling Hub to use a multiple-model approach to consider potential courses of the 2022-2023 influenza season including four scenarios covering higher and lower rates of vaccine impact and different levels of preexisting immunity [31-33]. The simultaneous consideration of multiple scenarios (sets of assumptions) allows modelers to consider what could happen under a variety of different circumstances. Results from the first round of the Influenza

Scenario Modeling Hub suggested in September of 2022 that hospitalizations in the 2022-2023 influenza season would be higher than recent seasons [32]. Early in the 2022-2023 season, projections for scenarios with lower population-level immunity demonstrated the plausibility of peak hospitalizations comparable to those of larger pre-pandemic influenza seasons while projections for scenarios with higher vaccine effectiveness and coverage were accompanied by substantial reductions in peak size and cumulative burden of hospitalizations due to influenza [32]. Subsequent rounds of the Influenza Scenario Modeling Hub undertaken in November and December 2022 reinforced these findings that projected peak hospitalizations could be comparable to those of larger pre-pandemic influenza seasons in the most plausible scenarios [32]. As demonstrated by several completed rounds of the COVID-19 Scenario Modeling Hub [34], these longer-term projections provide a useful information source for intervention planning, preparedness, and decision making [35-38]. By continuing to engage with the Scenario Modeling Hub in weekly meetings, CDC will be able to provide insight on which questions are of most interest for public health practice and preparedness during the 2023-2024 influenza season to help guide scenario development as well as lend expertise on datasets that may enhance modeling efforts. Results from the Influenza Scenario Modeling Hub may be used to inform potential peak timing and intensity. Additionally, influenza modelers within CDC will continue to engage with the broader infectious disease modeling community. Information on changing influenza epidemiology and surveillance systems will be regularly communicated across forecasting groups, modeling groups, and data curators. This will be achieved in part through coordinated efforts with partners in the Models of Infectious Disease Agent Study (MIDAS) Network [39].

Conclusion

The COVID-19 pandemic has changed many things that could influence trends observed in long-standing influenza surveillance systems. These changes have impacted ongoing efforts to describe influenza disease burden and forecast influenza activity and introduced new biases into

epidemiologic and clinical studies that rely on results of clinical testing. However, the pandemic has also provided opportunities for innovation that could better inform and support influenza efforts moving forward, including novel data sources such as the NHSN hospital admission dataset, the ability to compare the impact of multiple respiratory pathogens in different clinical settings, and increased engagement with the public and external partners. Pre-pandemic approaches used to inform influenza prevention and control efforts, such as surveillance, burden estimation, and modeling, will continue to be re-evaluated to ensure their reliability. State-level data may be used in the future to provide more spatially resolved estimates of burden, beyond the national burden estimates that are currently provided. The U.S. CDC Influenza Division remains committed to these key data and analytic activities, including the simultaneous monitoring of syndromic influenza surveillance with complimentary data sources, as well as to providing a central platform for collaboration and communication across disciplines and institutions to ensure that information to inform influenza prevention, situational awareness, and control remains robust and readily available.

Acknowledgments. None to declare.

Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Potential conflicts of interest. The authors declare no conflicts of interest.

Funding statement. The authors declare no funding sources.

References

1. Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020–2021. *MMWR Morb Mortal Wkly Rep*. 2021 Jul 7;70(29):1013. doi:10.15585/mmwr.mm7029a1
2. Merced-Morales A, Daly P, Abd Elal AI, et al. Influenza Activity and Composition of the 2022–

- 23 Influenza Vaccine—United States, 2021–22 Season. MMWR Morb Mortal Wkly Rep. 2022 Jul 7;71(29):913. doi:10.15585/mmwr.mm7129a1
3. Centers for Disease Control and Prevention. Past Seasons Estimated Influenza Disease Burden <https://www.cdc.gov/flu/about/burden/past-seasons.html> (accessed 8/11/2023)
 4. Centers for Disease Control and Prevention. 2022-2023 U.S. Flu Season: Preliminary In-Season Burden Estimates. <https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm> (accessed 8/11/2023)
 5. World Health Organization FluNet. Global Influenza Programme. <https://www.who.int/tools/flunet> (accessed 7/25/2023)
 6. Centers for Disease Control and Prevention. Weekly U.S. Influenza Surveillance Report. <https://www.cdc.gov/flu/weekly/index.htm> (accessed 9/6/2022)
 7. Centers for Disease Control and Prevention. Early Wave of Flu Brings Early Flu Hospitalizations. <https://www.cdc.gov/flu/spotlights/2022-2023/early-wave-hospitalizations.htm> (accessed 10/31/2022)
 8. Thomas CM, White EB, Kojima N, et al. Early and increased influenza activity among children—Tennessee, 2022–23 influenza season. MMWR Morb Mortal Wkly Rep. 2023 Jan 1;72(3):49. doi:10.15585/mmwr.mm7203a1
 9. Influenza Hospitalization Surveillance Network (FluSurv-NET) <https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm> (accessed 12/12/2022)
 10. FluView Interactive. <https://www.cdc.gov/flu/weekly/fluviewinteractive.htm> (accessed 8/10/2023)
 11. CDC Health Alert Network. Increased Respiratory Virus Activity Especially Among Children, Early in the 2022-2023 Fall and Winter. Distributed November 4, 2022. <https://emergency.cdc.gov/han/2022/han00479.asp>

12. Centers for Disease Control and Prevention. U.S. Influenza Surveillance: Purpose and Methods. <https://www.cdc.gov/flu/weekly/overview.htm> (accessed 12/12/2022)
13. HHS-Protect COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries. <https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh> (accessed 12/12/2022)
14. Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) <https://www.cdc.gov/surveillance/resp-lens/dashboard.html> (accessed 8/11/2023)
15. Respiratory Virus Hospitalization Surveillance Network (RESP-NET) <https://www.cdc.gov/surveillance/resp-net/dashboard.html> (accessed 8/11/2023)
16. Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness. *Influenza Other Respir. Viruses*. 2018 Jan;12(1):132-7. doi:10.1111/irv.12486
17. Centers for Disease Control and Prevention. Why CDC Estimates the Burden of Seasonal Influenza in the U.S. <https://www.cdc.gov/flu/about/burden/why-cdc-estimates.htm> (accessed 9/6/2022)
18. Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests—United States, August 23, 2021–March 12, 2022. *MMWR Morb Mortal Wkly Rep*. 2022 Apr 1;71(13):489. doi:10.15585/mmwr.mm7113e1
19. Reese H, Iuliano AD, Patel NN, et al. Estimated incidence of coronavirus disease 2019 (COVID-19) illness and hospitalization—United States, February–September 2020. *Clin. Infect. Dis*. 2021 Jun 15;72(12):e1010-7. doi:10.1093/cid/ciaa1780
20. Lutz CS, Huynh MP, Schroeder M, et al. Applying infectious disease forecasting to public health: a path forward using influenza forecasting examples. *BMC Public Health* 2019; 19:1659. doi: 10.1186/s12889-019-7966-8
21. McGowan CJ, Biggerstaff M, Johansson M, et al. Influenza Forecasting Working Group,

- Collaborative efforts to forecast seasonal influenza in the United States, 2015-2016. *Sci. Rep.* 9, 683 (2019). doi:10.1038/s41598-018-36361-9
22. Reich NG, McGowan CJ, Yamana TK, et al. Accuracy of real-time multi-model ensemble forecasts for seasonal influenza in the U.S. *PLoS Comput Biol* 2019; 15:e1007486. doi:10.1371/journal.pcbi.1007486
23. Reich NG, Brooks LC, Fox SJ, et al. A collaborative multiyear, multimodel assessment of seasonal influenza forecasting in the United States. *Proc. Natl. Acad. Sci. U.S.A.* 116, 3146–3154 (2019). doi:10.1073/pnas.1812594116
24. Cramer EY, Ray EL, Lopez VK, et al. Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the US. *Proc. Natl. Acad. Sci. U.S.A.*, 2022 Apr 12;119(15):e2113561119. . doi:10.1073/pnas.2113561119
25. Cramer EY, Huang Y, Wang Y, et al. The United States COVID-19 Forecast Hub dataset. *Sci. Data.* 2022 Aug 1;9(1):1-5. doi:10.1038/s41597-022-01517-w
26. Reich NG, Lessler J, Funk S, et al. Collaborative Hubs: Making the Most of Predictive Epidemic Modeling. *Am. J. Public Health.* 2022 Apr 13(0):e1-4. doi:10.2105/AJPH.2022.306831
27. Centers for Disease Control and Prevention. FluSight: Flu Forecasting. <https://www.cdc.gov/flu/weekly/flusight/index.html> (accessed 9/6/2022)
28. Reich NG, Ray EL. Collaborative modeling key to improving outbreak response. *Proc. Natl. Acad. Sci. U.S.A.* 2022 Apr 5;119(14):e2200703119. doi:10.1073/pnas.2200703119
29. Fox SJ, Lachmann M, Tec M, et al. Real-time pandemic surveillance using hospital admissions and mobility data. *Proc. Natl. Acad. Sci. U.S.A.* 2022 Feb 15;119(7):e2111870119. doi:10.1073/pnas.2111870119
30. Mathis SM, Webber AE, Basu A, et al. Evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza

hospitalizations. medRxiv. Preprint posted online December 11, 2023. doi:10.1101/2023.12.08.23299726.

31. Flu Scenario Modeling Hub GitHub. <https://github.com/midas-network/flu-scenario-modeling-hub> (accessed 8/11/2023)
32. Flu Scenario Modeling Hub. <https://fluscenariomodelinghub.org/> (accessed 8/11/2023)
33. Flu Scenario Modeling Hub Resources GitHub. https://github.com/midas-network/flu-scenario-modeling-hub_resources (accessed 8/11/2023)
34. COVID-19 Scenario Modeling Hub GitHub. <https://github.com/midas-network/covid19-scenario-modeling-hub> doi:10.5281/zenodo.6584489 (accessed 12/12/2022)
35. Borchering RK, Viboud C, Howerton E, et al. Modeling of future COVID-19 cases, hospitalizations, and deaths, by vaccination rates and nonpharmaceutical intervention scenarios—United States, April–September 2021. MMWR Morb Mortal Wkly Rep. 2021. doi:10.15585/mmwr.mm7019e3
36. Truelove S, Smith CP, Qin M, et al. Projected resurgence of COVID-19 in the United States in July–December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination. Elife. 2022 Jun 21;11:e73584. doi:10.7554/eLife.73584
37. Borchering RK, Mullany LC, Howerton E, et al. Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: a multi-model study. Lancet Reg. Health – Am. 2023 Jan 1;17:100398. doi:10.1016/j.lana.2022.100398
38. Biggerstaff M, Slayton RB, Johansson MA, Butler JC. Improving pandemic response: Employing mathematical modeling to confront coronavirus disease 2019. Clin. Infect. Dis. 2022 Mar 1;74(5):913-7. doi:10.1093/cid/ciab673
39. Models of Infectious Disease Agent Study. <https://midasnetwork.us> (accessed 12/12/2022)

Supplementary Files